.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,723,490

« Back to Dashboard

Claims for Patent: 5,723,490

Title: THF-containing sulfonamide inhibitors of aspartyl protease
Abstract:The present invention relates to a class of THF-containing sulfonamides which are aspartyl protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention.
Inventor(s): Tung; Roger D. (Arlington, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:08/424,819
Patent Claims: 1. A pharmaceutical composition comprising:

a) a pharmaceutically effective amount of a compound of the formula; ##STR310## wherein; each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2, --NR.sup.2 --S(O).sub.2 --, --NR.sup.2 --C(O)-- and --NR.sup.2 --C(O)--C(O)--;

each Het is independently selected from the group consisting of C.sub.3 -C.sub.7 carbocycle; C.sub.6 -C.sub.10 aryl; phenyl fused with heterocycle; and heterocycle; wherein any member of said Het may be optionally substituted with one or more substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, --N(R.sup.2)(R.sup.2), --NHOH, --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R.sup.2)(R.sup.2), --S(O).sub.2 --N(R.sup.2)(R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.6, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, --R.sup.6 and --O--R.sup.6 ;

each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl optionally substituted with R.sup.6 ;

each R.sup.3 is independently selected from the group consisting of H, Het, C.sub.1 -C.sub.6 alkyl and C.sub.2 -C.sub.6 alkenyl wherein any member of said R.sup.3, except H, may be optionally substituted with one or more substituents selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n --N(R.sup.2)(R.sup.2), Het, --CN, --SR.sup.2, --CO.sub.2 R.sup.2, NR.sup.2 --C(O)--R.sup.2 ;

each n is independently 1 or 2;

each D and D' is independently selected from the group consisting of R.sup.6 ; C.sub.1 -C.sub.5 alkyl, which may be optionally substituted with one or more groups selected from --OR.sup.2, --R.sup.3, --O--R.sup.6, --S--R.sup.6 and R.sup.6 ; C.sub.2 -C.sub.4 alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of --OR.sup.2, --R.sup.3, --O--R.sup.6 and R.sup.6 ; C.sub.3 -C.sub.6 carbocycle, which may be optionally substituted with or fused with R.sup.6 ; and C.sub.5 -C.sub.6 cycloalkenyl, which may be optionally substituted with or fused with R.sup.6 ;

each E is independently selected from the group consisting of Het; --O--Het; Het--Het; --O--R.sup.3 ; --NR.sup.2 R.sup.3 ; C.sub.1 -C.sub.6 alkyl, which may be optionally substituted with one or more groups selected from the group consisting of R.sup.4 and Het; and C.sub.2 -C.sub.6 alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of R.sup.4 and Het;

each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo, --NR.sup.2 --C(O)--R.sup.2 and --CN;

each R.sup.5 is independently selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl optionally substituted with aryl; and

each R.sup.6 is independently selected from the group consisting of aryl, carbocycle and heterocycle, wherein said carbocycle or heterocycle may be optionally substituted with one or more groups selected from the group consisting of oxo, --OR.sup.5, --R.sup.5, --N(R.sup.5) (R.sup.5), --N(R.sup.5)--C(O)--R.sup.5, --R.sup.5 --OH, --CN, --CO.sub.2 R.sup.5, --C(O)--N(R.sup.5) (R.sup.5), halo and --CF.sub.3 ;

b) one or more additional agents selected from the group consisting of other anti-viral agents and immunostimulators; and

c) a pharmaceutically acceptable carrier, adjuvant or vehicle,

wherein said pharmaceutical composition is orally administrable.

2. The pharmaceutical composition according to claim 1, wherein said other anti-viral agent or agents are protease inhibitors or reverse transcriptase inhibitors.

3. The pharmaceutical composition according to claim 2, wherein said protease inhibitor or inhibitors are HIV protease inhibitors.

4. The pharmaceutical composition according to claim 3, wherein said HIV protease inhibitor or inhibitors are selected from the group consisting of saquinavir (Ro 31-8959), MK 639, ABT 538 (A80538), AG 1343, XM 412, XM 450 and BMS 186,318.

5. The pharmaceutical composition according to claim 2, wherein said reverse transcriptase inhibitor or inhibitors are nucleoside analogs.

6. The pharmaceutical composition according to claim 5, wherein said nucleoside analog or analogs are selected from the group consisting of zidovudine (AZT), dideoxycytidine (ddC), didanosine (ddI), stavudine (d4T), 3TC, 935U83, 1592U89 and 524W91.

7. The pharmaceutical composition according to claim 2, wherein said reverse transcriptase inhibitor or inhibitors are non-nucleo side analogs.

8. The pharmaceutical composition according to claim 7, wherein said non-nucleoside reverse transcriptase inhibitor or inhibitors are delavirdine (U90) or nevirapine.

9. A method for preventing HIV infection in a mammal comprising the step of administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition according to claim 1.

10. A method for treating HIV infection in a mammal comprising the step of administering to said mammal a pharmaceutically effective amount of a pharmaceutical composition according to claim 1.

11. A method of treating or preventing HIV infection in a mammal comprising the steps of:

a) administering to the mammal a composition comprising:

(i) a pharmaceutically effective amount of a compound of the formula: ##STR311## wherein: each R.sup.1 is independently selected from the group consisting of --C(O)--, --S(O).sub.2 --, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2, --NR.sup.2 --S(O).sub.2 --, --NR.sup.2 --C(O)-- and --NR.sup.2 --C(O)--C(O)--;

each Het is independently selected from the group consisting of C.sub.3 --C.sub.7 carbocycle; C.sub.6 -C.sub.10 aryl; phenyl fused with heterocycle; and heterocycle; wherein any member of said Het may be optionally substituted with one or more substituents selected from the group consisting of oxo, --OR.sup.2, --R.sup.2, N(R.sup.2) (R.sup.2), --NHOH, --R.sup.2 --OH, --CN, --CO.sub.2 R.sup.2, --C(O)--N(R)(R.sup.2), --S(O).sub.2 --N(R.sup.2)(R.sup.2), --N(R.sup.2)--C(O)--R.sup.2, --C(O)--R.sup.2, --S(O).sub.n --R.sup.2, --OCF.sub.3, --S(O).sub.n --R.sup.6, --N(R.sup.2)--S(O).sub.2 (R.sup.2), halo, --CF.sub.3, --NO.sub.2, --R.sup.6 and --O--R.sup.6 ;

each R.sup.2 is independently selected from the group consisting of H and C.sub.1 -C.sub.3 alkyl optionally substituted with R.sup.6 ;

each R.sup.3 is independently selected from the group consisting of H, Het, C.sub.1 -C.sub.6 alkyl and C.sub.2 -C.sub.6 alkenyl wherein any member of said R.sup.3, except H, may be optionally substituted with one or more substituents selected from the group consisting of --OR.sup.2, --C(O)--NH--R.sup.2, --S(O).sub.n --N(R.sup.2)(R.sup.2), Het, --CN, --SR.sup.2, --CO.sub.2 R.sup.2, NR.sup.2 --C(O)--R.sup.2 ;

each n is independently 1 or 2;

each D and D' is independently selected from the group consisting of R.sup.6 ; C.sub.1 -C.sub.5 alkyl, which may be optionally substituted with one or more groups selected from --OR.sup.2, --R.sup.3, --O--R.sup.6, --S--R.sup.6 and R.sup.6 ; C.sub.2 -C.sub.4 alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of --OR.sup.2, --R.sup.3, --O--R.sup.6 and R.sup.6 ; C.sub.3 -C.sub.6 carbocycle, which may be optionally substituted with or fused with R.sup.6 ; and C.sub.5 -C.sub.6 cycloalkenyl, which may be optionally substituted with or fused with R.sup.6 ;

each E is independently selected from the group consisting of Het; --O--Het; Het--Het; --O--R.sup.3 ; --NR.sup.2 R.sup.3 ; C.sub.1 -C.sub.6 alkyl, which may be optionally substituted with one or more groups selected from the group consisting of R.sup.4 and Het; and C.sub.2 -C.sub.6 alkenyl, which may be optionally substituted with one or more groups selected from the group consisting of R.sup.4 and Het;

each R.sup.4 is independently selected from the group consisting of --OR.sup.2, --C(O)--NHR.sup.2, --S(O).sub.2 --NHR.sup.2, halo, --NR.sup.2 --C(O)--R.sup.2 and --CN;

each R.sup.5 is independently selected from the group consisting of H and C.sub.1 -C.sub.4 alkyl optionally substituted with aryl; and

each R.sup.6 is independently selected from the group consisting of aryl, carbocycle and heterocycle, wherein said carbocycle or heterocycle may be optionally substituted with one or more groups selected from the group consisting of oxo, --OR.sup.5, --R.sup.5, --N(R.sup.5)(R.sup.5), --N(R.sup.5)--C(O)--R.sup.5, --R.sup.5 --OH, --CN, --CO.sub.2 R.sup.5, --C(O)--N(R.sup.5)(R.sup.5), halo and --CF.sub.3 ; and

ii) a pharmaceutically acceptable carrier, adjuvant or vehicle,

wherein said pharmaceutical composition is orally administrable; and

b) concurrently or sequentially administering to the mammal one or more additional agents selected from the group consisting of other anti-viral agents and immunostimulators.

12. The method according to claim 11, wherein said other anti-viral agent or agents are protease inhibitors or reverse transcriptase inhibitors.

13. The method according to claim 12, wherein said protease inhibitor or inhibitors are protease inhibitors.

14. The method according to claim 13, wherein said HIV protease inhibitor or inhibitors are selected from the group consisting of saquinavir (Ro 31-8959), MK 639, ABT 538 (A80538), AG 1343, XM 412, XM 450 and BMS 186,318.

15. The method according to claim 11, wherein said reverse transcriptase inhibitor or inhibitors are nucleoside analogs.

16. The method according to claim 15, wherein said nucleoside analog or analogs are selected from the group consisting of zidovudine (AZT), dideoxycytidine (ddC), didanosine (ddI), stavudine (d4T), 3TC, 935U83, 1592U89 and 524W91.

17. The method according to claim 12, wherein said reverse transcriptase inhibitor or inhibitors are non-nucleoside analogs.

18. The method according to claim 17, wherein said non-nucleoside reverse transcriptase inhibitor or inhibitors are delavirdine (U90) or nevirapine.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc